维生素B6响应性和不响应性囊腺尿症:两个变异的分子形式
概括
维生素B6响应的囊氨尿症显示,皮里多克萨尔酸盐与囊酶活性增加. 这种酶在免疫化学上与正常的cystathionase相同,与B6无反应病例不同.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 囊氨尿症是一种罕见的代谢障碍.
- 维生素B6是参与氨基酸代谢的酶的关键辅因子.
- 在囊腺尿症中,特定的酶缺陷并不总是很清楚.
研究的目的:
- 研究维生素B6响应性和不响应性cystathioninuria中的cystathionase的活性和免疫化学特性.
- 为了确定皮里多克萨尔酸盐能否恢复受影响细胞系中的酶功能.
主要方法:
- 对淋巴细胞系提取物进行酶活性测定.
- 在体外补充皮里多克索酸盐.
- 使用抗血清对人类肝脏cystathionase的免疫扩散测定.
主要成果:
- 皮里多克萨尔酸盐在维生素B6反应良好的患者的细胞提取物中显著增加了囊酶活性.
- 响应患者的囊酶蛋白在免疫化学上与正常的囊酶相同.
- 从维生素B6无反应患者的细胞提取物中没有观察到活性或免疫化学标识的增加.
结论:
- 维生素B6响应型的囊腺尿症可能涉及影响酸盐结合或酶构成的突变.
- 氨酸酶是这种维生素B6反应良好的患者可能缺乏的酶.
- 没有B6反应的患者可能有不同的酶缺陷或更严重的突变.
相关概念视频
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacodynamic Responses: Different Types
Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


